Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Enlicitide Decanoate and Semaglutide in Healthy Adults
NCT06699329Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to 24 hours of Enlicitide Decanoate, Area Under the Concentration-Time Curve from Time 0 to 24 hours of Semaglutide and 4 more. Started Jan 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06699329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699329.